Fourrts (India) Laboratories Pvt Ltd Risk Report

⚖️ Legal & Regulatory

Fourrts (India) Laboratories Pvt Ltd has faced significant regulatory challenges in recent times, highlighting potential risks in compliance with international standards. The involvement of the WHO in warning against contaminated products evidences serious compliance issues. However, the company has had some relief in local regulatory matters.

• The World Health Organization (WHO) issued a warning about contaminated cough syrup supplied to Iraq by Fourrts 🗓 on August 7, 2023.
• An alert was raised by WHO about an India-made contaminated syrup batch from Fourrts in Iraq, highlighting potential public health risks 🗓 on August 8, 2023.
• Relief was granted to Fourrts India by the Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) regarding assessment of physician samples 🗓 on August 24, 2023.

🏗️ Operational & Business Continuity

Fourrts has faced significant operational disruptions in the past, with incidents affecting their inventory and business continuity. A past event underscores the operational risks inherent in their manufacturing operations.

• A fire destroyed medicines worth ₹5 crore in Chennai, drastically impacting their inventory and potentially disrupting distribution 🗓 on May 27, 2018.